Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29558224 | 1.00 | SIGMAR1 (1.00) | SIGMAR1KCNH2MAPTMAPK1HTT | |
| SCHEMBL467173 | 0.91 | SIGMAR1 (0.83) | SIGMAR1KCNH2 | |
| SCHEMBL17530637 | 0.90 | SIGMAR1 (0.82) | SIGMAR1KCNH2 | |
| Oxalic Acid SCHEMBL4521956 | 0.88 | SIGMAR1 (0.79) | SIGMAR1KCNH2 | |
| SCHEMBL19988158 | 0.87 | SIGMAR1 (0.85) | SIGMAR1KCNH2 | |
| SCHEMBL467027 | 0.85 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| Formic Acid SCHEMBL2360173 | 0.85 | SIGMAR1 (0.76) | SIGMAR1KCNH2 | |
| SCHEMBL4516818 | 0.85 | SIGMAR1 (0.79) | SIGMAR1KCNH2 | |
| SCHEMBL28470749 | 0.85 | SIGMAR1 (0.73) | SIGMAR1KCNH2 | |
| SCHEMBL467323 | 0.84 | SIGMAR1 (1.00) | SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010128-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2019-01-10 | — | — | US | claimed |
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | claimed |
| US-20160310501-A1 | GABAPENTINOIDS AND SIGMA RECEPTOR LIGANDS COMBINATIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-10-27 | — | — | US | claimed |
| US-20160220574-A1 | NSAID AND SIGMA RECEPTOR LIGAND COMBINATIONS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-08-04 | — | — | US | claimed |
| US-20160151377-A1 | USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS) | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-06-02 | — | — | US | claimed |
| US-20160058771-A1 | ALPHA-2 ADRENOCEPTOR AND SIGMA RECEPTOR LIGAND COMBINATIONS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-03-03 | — | — | US | claimed |
| EP-2571501-B1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | claimed |
| EP-2276744-B1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | ESTEVE LABOR DR (ES) | 2014-10-01 | — | — | EP | claimed |
| US-20140107111-A1 | USE OF SIGMA LIGANDS IN DIABETES TYPE-2 ASSOCIATED PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-04-17 | — | — | US | claimed |
| EP-2709620-A1 | USE OF SIGMA LIGANDS IN DIABETES TYPE-2 ASSOCIATED PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-03-26 | — | — | EP | claimed |
| EP-2415471-A1 | Use of sigma ligands in opioid-induced hyperalgesia | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-02-08 | — | — | EP | claimed |
| WO-2011144721-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-24 | — | — | WO | claimed |
| EP-2388005-A1 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-11-23 | — | — | EP | claimed |
| EP-2353591-A1 | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | claimed |
| US-20110112095-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-12 | — | — | US | claimed |
| US-20100190781-A1 | SIGMA RECEPTOR INHIBITORS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-07-29 | — | — | US | claimed |
| US-7696199-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-13 | — | — | US | claimed |
| EP-2116539-A1 | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| WO-2009130310-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-29 | — | — | WO | claimed |
| US-20080125416-A1 | Sigma Receptor Inhibitors | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2008-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107111-A1 | USE OF SIGMA LIGANDS IN DIABETES TYPE-2 ASSOCIATED PAIN | OPRL1, SIGMAR1, OPRK1 | SIGMAR1 2/4885KCNH2 1081/4885MAPT 3712/4885 |
| US-20160151377-A1 | USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS) | OPRL1, NPSR1, SIGMAR1 | SIGMAR1 3/4885KCNH2 916/4885MAPT 3742/4885 |
| US-20160058771-A1 | ALPHA-2 ADRENOCEPTOR AND SIGMA RECEPTOR LIGAND COMBINATIONS | ADRB2, ADRA2C, ADRA2A | SIGMAR1 7/4885KCNH2 947/4885MAPT 2387/4885 |
| US-20160310501-A1 | GABAPENTINOIDS AND SIGMA RECEPTOR LIGANDS COMBINATIONS | SIGMAR1, OPRL1, OPRM1 | SIGMAR1 1/4885KCNH2 2068/4885MAPT 1538/4885 |
| US-20080125416-A1 | Sigma Receptor Inhibitors | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885KCNH2 1365/4885MAPT 1481/4885 |
| US-20190010128-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | OPRK1, OPRD1, SIGMAR1 | SIGMAR1 3/4885KCNH2 1308/4885MAPT 3072/4885 |
| US-20110112095-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | OPRK1, OPRD1, SIGMAR1 | SIGMAR1 3/4885KCNH2 1308/4885MAPT 3072/4885 |
| US-20160220574-A1 | NSAID AND SIGMA RECEPTOR LIGAND COMBINATIONS | SIGMAR1, OPRL1, OPRK1 | SIGMAR1 1/4885KCNH2 3492/4885MAPT 3886/4885 |
| US-20100190781-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885KCNH2 1365/4885MAPT 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.